Amgen’s Repatha® Cuts First‑Time Major Cardiovascular Event Risk by 25% in VESALIUS‑CV Trial

In a landmark Phase 3 trial dubbed VESALIUS‑CV, biotechnology firm Amgen found that its PCSK9 inhibitor Repatha® (evolocumab) lowered the risk of a first major adverse cardiovascular event (MACE) by 25% in high‑risk adults who had no prior heart attack or stroke, when added to statin or other LDL‑C‑lowering therapies. The trial enrolled more than 12,000 participants with atherosclerosis or diabetes, treated for a median of approximately 4.6 years. Among them, Repatha® also drove a 36% reduction in heart‑attack risk and a 19% reduction for a broader composite endpoint including ischemia‑driven revascularization. Notably, the lipid sub‑study showed a median achieved LDL‑C of 45 mg/dL in the evolving arm versus 109 mg/dL in placebo. No new safety signals emerged and tolerability remained consistent with existing prescribing information. These results reinforce the importance of intensive LDL‑C reduction in both primary and secondary cardiovascular prevention — even before the first heart event. #cardiovascularhealth #cholesterollowering #Repatha #Amgen #SlimScan #GrowthStocks #CANSLIM